▲ +83.36% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Bolt Biotherapeutics in the last 3 months. The average price target is $41.00, with a high forecast of $45.00 and a low forecast of $37.00. The average price target represents a 83.36% upside from the last price of $22.36.
The current consensus among 4 investment analysts is to buy stock in Bolt Biotherapeutics.
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.